Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price target of $36.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Matthew Caufield has given his Buy rating due to a combination of factors, primarily centered around 4D Molecular Therapeutics’ promising data from its Phase 2b PRISM trial for the 4D-150 gene therapy candidate targeting wet AMD. The trial data indicates significant clinical benefit with robust reduction in supplemental aflibercept injections and a noteworthy portion of patients achieving injection freedom, highlighting the therapy’s potential to reduce treatment burden.
Additionally, the upcoming Phase 3 4FRONT trials are strategically designed to further assess efficacy in both treatment-naïve and previously treated patients, which strengthens the case for 4D-150’s differentiated profile. The safety profile of 4D-150 is also favorable, with low incidence of inflammation and a manageable safety profile comparable to standard anti-VEGF treatments. These positive aspects underpin the reiteration of a Buy rating and a price target of $36.
In another report released today, Barclays also maintained a Buy rating on the stock with a $45.00 price target.